LAAI
Topics
Meeting category
Date(s)
21 May 2025 - 22 May 2025
Location
New Orleans, LA, United States
Meeting type
In-Person Meeting
Virology Education
Register Here

1st International Workshop on Long Acting Anti-Infectives (LAAI) 2025

Register Here

Related Enduring Materials

Videos
1
General
Join Us!

The 1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025 is scheduled to take place as an in-person meeting from 21-22 May 2025 in New Orleans, LA, United States.

Don’t miss this opportunity to connect with experts and explore the latest advancements in long-acting therapeutics!

What's New?
  •  ​​​​​​​Venue is confirmed. The workshop will take place at the Renaissance New Orleans Pere Marquette French Quarter Area Hotel, located in New Orleans, United States.
marriott new orleans (1)


 

About this Program

The International Workshop On Long Acting Anti-Infectives (LAAI) is a crucial platform for advancing the development, implementation, and scale-up of long-acting and extended-release (LA/ER) anti-infective therapies. This 1st edition of the workshop will explore the transformative potential of LA/ER drug delivery in infectious disease management, with a focus on recent breakthroughs in HIV prevention and treatment.

Attendees will discuss the clinical application of these therapies in populations with historically low adherence, including pediatric patients, pregnant and breastfeeding women, and individuals experiencing homelessness.

By sharing knowledge on trial design, safety, efficacy, and implementation strategies, this 2-day in-person workshop will contribute to the global effort to improve health outcomes, extending the benefits of these therapies beyond HIV to other infectious diseases like tuberculosis, malaria, and viral hepatitis.

Organizing Committee
General Information 
Who Should Attend?
- Clinicians;
- Researchers;
- Clinical pharmacologists;
- Pharmacists;
- Industry representatives;
- Regulatory scientists;
- Government representatives;
- Post-graduate students;
- Other professionals involved in the development of novel anti-infective therapy.
Meeting Objectives
This meeting aims to:

- Foster interdisciplinary collaboration to accelerate the development and evaluation of long-acting anti-infective interventions targeting a spectrum of infectious diseases;

- Discuss the efficacy, safety, and accessibility of novel agents across diverse populations;

- Outline the patterns of anti-infective drug resistance and devise strategies to mitigate the impact of drug resistance on treatment outcomes and public health;

- Develop actionable recommendations aimed at enhancing access, adherence, and outcomes for LA anti-infective treatments.
Practical Information 
Venue
The 1st International Workshop on Long Acting Anti-Infectives (LAAI) 2025 will be hosted at:

Hotel: Renaissance New Orleans Pere Marquette French Quarter Area Hotel
Address: 817 Common St, New Orleans, LA 70112, United States

Distance from Louis Armstrong New Orleans International Airport: 25 km
Travel
Travel is not included in the registration fee.
Accommodation
Accommodation is not included in the registration fee.
Badges
All participants are requested to wear the badge at all times during the conference to ensure admission to the meeting.
Certificate of Attendance
A certificate of attendance will be sent to you after successfully completing the workshop and post-workshop survey.
Language
The official language of the workshop is English.
Translation will not be provided.
Enduring Materials
Enduring materials will be available here 3 weeks after the conclusion of the workshop.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the workshop participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Registration
Registration is open!
Register here
Fees and Conditions

Regular Delegates-
In-Person

Industry** - In-Person

Early Fee (payment before/on 17 January 2025) 

$695,00

$995,00

Standard Fee (payment before/on 28 March 2025)

$845,00

$1.145,00

Late Fee (payment from 29 March 2025)

$945,00

$1.245,00

Discounts

Early-Career Investigators (ECI) / Regular Delegates from Resource-Limited Settings (RLS)* WITH accepted abstract

50% Off Early Fee

Early-Career Investigators (ECI) / Regular Delegates from Resource-Limited Settings (RLS)* WITHOUT accepted abstract

 50% Off Current Regular Delegate Fee

NGO Representatives / Government Representatives (i.e. MOH, NIH, NIAID, etc.) / Advocates

 50% Off Current Regular Delegate Fee

Representatives of sponsoring industry **

Please contact the conference secretariat

Representatives of endorsing organizations

 25% Off Current Regular Fee

* Countries included in the low-income and lower-middle-income economies of the World Bank Classification.

** Industry representatives may receive a discount based on the level of support provided to the event. For more support and registration information, please contact us via Michelle.Wu@amededu.com

If you have financial concerns or are eligible for a discount, please contact the conference secretariat via Michelle.Wu@amededu.com

Important

  • We strongly advise that you register early to ensure your registration. Registration will close when the capacity of the venue is reached.

  • Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full prepayment has been received and a confirmation of your registration has been sent.

Registration Fee Includes
For onsite attendees:

- Access to all scientific sessions, including poster area

- Conference pack, including abstract book and program

- Refreshments during the coffee breaks

- Buffet lunch on meeting days


IMPORTANT:

- No day rate is available

- Payment can only be made by credit card.

- Virology Education reserves the right to cancel improper registrations. Claims for a refund will not be honored.
Group Registration
For registration of groups larger than 5 participants, please contact the Conference Secretariat at Michelle.Wu@amededu.com.
Early-Career Investigators (ECI) / Academia from Resource-limited Settings (RLS)
We are pleased to offer 50% discount on the Early Fee for early-career investigators and academia from low-income and lower-middle-income countries with an accepted abstract and a 50% discount on the Standard Fee without an accepted abstract.

IMPORTANT: The discount is offered to the presenting author only.

To be eligible as an ECI, one should either be a current Master/PhD student or have obtained an MD/PharmD/PhD degree in the last five years. An application form needs to be completed by a supervisor and received by the Virology Education secretariat at least two weeks prior to the start of the workshop. Virology Education will contact the early-career investigator with instructions regarding the registration procedure.
Downloads:
Payment
By credit card only: online or by written authorization (see online registration).

Please contact the conference secretariat via Michelle.Wu@amededu.com if you need to make alternative arrangements.
Cancellation Policy
In case of cancellation, the following refunds are applicable:

- Cancellation before/on 14 April 2025: 50% refund (minus an administration fee of $40)

- Cancellation after 14 April 2025: Unfortunately, no refund will be given

If you are unable to attend the conference, a substitute delegate is always welcome at no extra charge, provided that a letter of authorization from the original participant has been received and the conference secretariat has been notified of the name of the substitute delegate before 30 April 2025. A statement (email/letter) of cancellation must be sent to Virology Education.
Liability and Insurance
By registering for the conference, participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Media Registration
In order to register as a media participant for the Conference, the conference secretariat needs to receive:

1. Proof of accreditation
2. Valid identification (e.g. passport)
3. A letter from your assignment giver stating the details of your assignment (e.g. editor)
4. At least 3 previous written assignments in recognized outlets on HIV. If you are a freelance journalist, the assignments can be from different (recognizable) news outlets. Links to online publications are accepted
5. The website of the publication(s)/blog(s) that will be featuring your story on this workshop

A complimentary or reduced registration fee may apply for accredited media participants depending on availability. Preference will be given to credible print and online news sources. Please contact the conference secretariat for registration conditions.

We would like to receive a copy of your workshop report/ article once it is finalized.
All credentials will be verified by the Organizing Committee of the Workshop. Media representatives are kindly requested to register by sending the above-mentioned information to info@amededu.com.

Important: Media is restricted to the written press. Recording on film or photo is not allowed. Virology Education will request a copy of the written piece once it is finalized. Media representatives must also agree to abide by the 2024 embargo policy.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop. In case of cancellation of the meeting due to unforeseen circumstances, Virology Education cannot be held responsible for expenses made for travel, accommodation, visa applications, etc.
Program
Program

Day 1 - Wednesday, 21 May 2025

Opening and Session 1: Advancing Long-Acting Anti-Infectives: Regulatory Insights and Clinical Impact - 8:30
8:30 AM
Welcome Coffee & Poster Viewing 
9:00 AM
Opening of the Workshop - Welcome to New Orleans
Charles Flexner
Charles Flexner, MD
Johns Hopkins University School of Medicine, United States
Fred A. Lopez
LSUHSC School of Medicine, United States
9:10 AM
Long-Acting Anti-Infectives: Where Do We Stand? 
Charles Flexner
Charles Flexner, MD
Johns Hopkins University School of Medicine, United States
9:30 AM
Pharmacological Considerations for Various Routes of LAAI Administration
Perazzolo, Simone 2024
Simone Perazzolo, PHD, MSC
University of Washington, United States
9:50 AM
Regulatory Considerations for Long-Acting Anti-Infectives: Challenges and Opportunities 
Kellie Schoolar Reynolds 2021
Kellie Schoolar Reynolds, PharmD
Center for Drug Evaluation and Research, FDA, United States
10:10 AM
Panel Discussion / Q&A
10:45 AM
Coffee Break
Session 2: HIV Prevention - 11:15
11:15 AM
Current and Future Perspectives in HIV Treatment: Approved Drugs and Therapies in Development 
Elion, Rick
Richard Elion, MD
Washington Health Institute, United States
11:35 AM
Long-Acting Antiretroviral Monoclonal Antibodies: Revolutionizing HIV Prevention 
Gelderblom, Huub 2025
Huub Gelderblom, MD, MSc, PhD, MPH
HVTN (HIV Vaccine Trials Network) / Fred Hutchinson Cancer Center, United States
11:55 AM
Analysing the Impact of the USAID Freeze and Terminations on the Introduction of Injectable Cabotegravir for PrEP
12:10 PM
Oral Abstract Presentation #1 - Proof-of-Concept Study of Oral VH4004280, a New HIV-1 Capsid Inhibitor
Paul Benn
United Kingdom
12:20 PM
Q&A
12:40 PM
Lunch
Industry-Supported Symposium - 1:30
1:30 PM
Industry-Supported Symposium - The full program of "Industry-Supported Symposium" can be visited under the "Symposium" Tab
Session 3: HIV Treatment - 2:45
2:45 PM
Implementation Challenges in LMICs
3:05 PM
Emerging Data on Long-Acting Antiretrovirals and Resistance 
Marzinke, Mark 2025
Mark Marzinke, PhD, DABCC, FADLM
Johns Hopkins University School of Medicine, United States
3:25 PM
Oral Abstract Presentation #2 - Utilization and Effectiveness of Cabotegravir + Rilpivirine in People with HIV (PWH) with Viremia at Treatment Initiation
Richard A. Elion
United States
3:35 PM
Oral Abstract Presentation #3 - Novel Ultra-Long-Acting Injectable Formulations of Bictegravir
Ron Liu
United States
3:45 PM
Panel Discussion
4:15 PM
Coffee Break & Poster Viewing
Session 4: Navigating Long-Acting Anti-Infective Therapies: Clinical Evidence and Practical Application in Key Populations  - 4:45
4:45 PM
Pharmacological Considerations of Long-Acting Anti-Infective Administration Routes During Pregnancy 
Robert Bies
Robert R. Bies, Pharm.D., Ph.D., FISoP
School of Pharmacy and Pharmaceutical Sciences University at Buffalo, United States
5:05 PM
Long-Acting Anti-Infectives for the Pediatric and Adolescent Population 
Natella Rakhmanina
Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVS
Children’s National Hospital, United States
5:25 PM
Oral Abstract Presentation #4 - Facilitators and Barriers to Long-Acting Injectable Antiretroviral Therapy Uptake among Youth Living with HIV in Cape Town, South Africa: A COM-B Analysis
Sheree Schwartz
United States
5:35 PM
Oral Abstract Presentation #5 - Cabotegravir and Rilpivirine in Pregnancy: A Multi-Center Study Evaluating HIV viral suppression, Perinatal and Neonatal Outcomes
William Short
United States
5:45 PM
Q&A
6:00 PM
End of Day 1  
7:30 PM
Networking Dinner

Day 2 - Thursday, 22 May 2025

Session 5: Long-Acting Solutions in Tuberculosis Care - 9:10
9:10 AM
Clinical Development of Long-Acting Formulations for Treatment and Prevention of Tuberculosis
Kimberly Scarsi
Kimberly Scarsi, PharmD, MS, FCCP
University of Nebraska Medical Center (UNMC), United States
9:30 AM
Use of Modelling and Simulation in Optimization LA Therapies for Tuberculosis
Rada Savic
Rada Savic, PhD
University of California, San Francisco
9:50 AM
Oral Abstract Presentation #6 - Development of long-acting Telacebec (Q203) for treatment of M. tuberculosis, M. ulcerans and M. leprae
Martina Kovarova
United States
10:00 AM
Oral Abstract Presentation #7 - First in Human Dose Predictions Scaled from Preclinical Pharmacokinetics for LAI Rifabutin
Doaa Ahmed Mohamed
United Kingdom
10:10 AM
Q&A 
10:40 AM
Coffee Break   & Poster Viewing
Session 6: Long-Acting Anti-Infectives: Today and Tomorrow  - 11:25
11:25 AM
The LONGEVITY Project: Long-Acting Anti-Infectives for Malaria, Hepatitis C, and Tuberculosis 
Owen, Andrew
Andrew Owen, BSS, MSC, PhD, FSB
University of Liverpool, United Kingdom
11:45 AM
Long-Acting Anti-Infectives in Resource-Limited Settings 
Venter, Francois 2023
François Venter, MD, FCP, PhD
Ezintsha, University of the Witwatersrand, South Africa
12:05 PM
Prodrugs Create Ultra-Long-Acting Slow Effective Release Therapies
Benson J. Edagwa, PhD
University of Nebraska Medical Center, United States
12:25 PM
Oral Abstract Presentation #8 - LAPaL: your free digital compass in the evolving long-acting therapeutics landscape
Lobna Gaayeb
Switzerland
12:35 PM
Panel Discussion
1:00 PM
Lunch
Session 7: Monoclonal Antibodies in the Treatment of Respiratory and Other Infections  - 2:00
2:00 PM
Monoclonal Antibodies for RSV Prevention 
Hak, Sarah 2025
Sarah Hak, MD
Wilhelmina Children’s Hospital, University Medical Center Utrecht, The Netherlands
2:20 PM
Long-Acting Therapies for Emerging Infections: Insights from COVID-19 
Daniel Kuritzkes
Daniel Kuritzkes, MD
Brigham and Women's Hospital / Harvard Medical School, United States
2:40 PM
Oral Abstract Presentation #9 - VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study
Rulan Griesel
United States
2:50 PM
Panel Discussion
3:20 PM
Closing Remarks 
3:30 PM
End of Program  
Symposium
Wednesday, 21 May 2025

SymposiumTitle: PrEP today. Data discussions on an HIV-1 PrEP option

Symposium Time: 1:30 PM - 2:45 PM

Program Supporter: ViiV Healthcare

Program Description: During this educational session, attendees will learn about an alternative PrEP option to help prevent HIV in their patients. The program will review important information, clinical data, and dosing and administration, and provide guidance on identifying patients who would benefit. In addition, the program will also feature a Patient Ambassador who will share their personal experience with this PrEP option and discuss how it impacted their life.

Speaker Information
  • ​​​​​​Dr. Heidi Swygard, ViiV Healthcare Medical
     
  • Luis O., Patient Ambassador
     
  • Dr. Theo Hodge, MD, Washington Health Institute

Program Supporter

We are ViiV Healthcare: a specialist pharmaceutical company 100% dedicated to HIV medicines and research and focused on people living with HIV and AIDS. At ViiV Healthcare we do things differently. From our unique origins to our innovative medicines, we push the boundaries of what people think is possible in HIV treatment and care. Born out of a partnership between GSK and Pfizer in 2009, with Shionogi joining in 2012, at ViiV Healthcare we are determined to help end the HIV epidemic. Our one focused goal unites our employees located across the globe, with their expertise in research, manufacturing, policy and more, all guided by our mission to be here until HIV is not.

Visit www.viivhealthcare.com for more information.

Abstracts
The Abstract Portal is still Open! Click the "Submit" button to share your Research.
Submit
Abstracts
  • The International Workshop On Long Acting Anti-Infectives 2025 accepts new original data as well as encored abstracts. All abstracts must contain up-to-date information at the time of the workshop.
     
  • 50% discount on the early fee will be offered for early-career professionals with an accepted abstract. A 50% discount on the regular registration fee is offered to early-career professionals without an accepted abstract. The requirements for the application are specified here.

  • Abstract submitters are strongly encouraged to use person-first language in their abstracts. View the video tutorial and guidelines here

  • Abstract presenters are expected to attend the workshop in-person to present their abstract.

Categories for Abstract Submission
For purposes of review and programming, abstracts are divided into topical categories. The selection of the most appropriate category is important as it determines who reviews your abstract. The Program Committee reserves the right to reassign your abstract to a more appropriate category.

Abstract categories:
- Long-Acting Formulations for Treatment of Infections
- Prevention of Key Infections with Long-Acting Formulations
- Regulatory, End-User, and Implementation Issues
- Long-Acting Anti-Infectives for Key Populations
- Future Directions and Novel Platforms for Long-Acting Anti-Infective Therapies
- Monoclonal Antibodies
General Guidelines
Abstracts should contain the following four components:

- Background: A concise statement of the issue under investigation or a hypothesis;

- Material and Methods: The experimental methods used (including the statistical analyses employed);

- Results: Specific findings (promises such as "to be completed" or "to be presented" are not acceptable);

- Conclusions: A summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as "the results will be discussed" are not acceptable).

Please note that abstracts cannot be accepted if tables or graphs are included. The maximum word count for the abstract body is 500 words.

Abstracts are considered official communications to the conference and will be treated confidentially. Submitters of accepted abstracts agree to attend the meeting and present their abstract as scheduled.

We encourage you to use person-first language in your abstract(s). View our guidelines here: https://academicmedicaleducation.com/person-first-language
Abstract Submission
Authors can submit their abstracts electronically until the deadline. You will be redirected to the submission website. Please follow the step-by-step directions to upload the abstract. To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.
Poster Presentation Instructions
Poster presenters are expected to attend onsite.
Posters need to meet the following dimensions A0 size (approx. 33" x 47") in portrait format.
Please display the number of your poster in the upper right corner of your poster.

Once onsite:
Poster presenters are requested to stand near their posters during the poster session.
We advise you to prepare handouts of your poster in Letter or A4 format.
Please hang your posters as early as possible. All posters must be displayed from the opening session to the closure of the workshop.
Pushpins and/or velcro will be provided.
Committees
Organizing Committee

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.

Scientific Committee

The members of Scientific Committee are hand-picked by the Organizing Committee and the workshop secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

  • Marta Boffito, MD, PhD, FRCP, MBA - Chelsea and Westminster Hospital NHS Foundation Trust/Imperial College London, United Kingdom

  • Jordan Feld, MD, MPH - Toronto Centre for Liver Disease, Canada

  • Beatriz Grinsztejn, MD, PhD - Instituto de Pesquisa Clinica Evandro Chagas-Fiocruz, Brazil

  • Rodney JY Ho, PhD, FAAAS, FAAPS - University of Washington, United States

  • Cissy Kityo Mutuluuza MBChB, M.Sc, PhD - Joint Clinical Research Centre, Uganda

  • Andrew Owen, BSS, MSC, PhD, FSB - University of Liverpool, United Kingdom

  • Nicholas Paton, MD, FRCP - National University of Singapore, Singapore

  • Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVS - Children’s National Hospital, United States

  • David L. Thomas, MD - Johns Hopkins University School of Medicine, United States

Support
Founding Sponsor

Support provided by ViiV Healthcare.

Supporter Level Sponsor
Support Our Initiative

Financial backing helps us deliver an impactful meeting experience to the benefit of healthcare professionals and community representatives.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
 
To show your commitment to the cause and get in touch with us for a tailored support package, please contact Ms. Daria Bohdanova at Daria.Bohdanova@amededu.com or call +31 30 230 7140.

Benefits of Support

By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

  • Symposium opportunities
  • Non-commercial interviews with company representatives
  • Verbal acknowledgment during the program 
  • Discounted and complimentary registrations for your representatives
  • Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
  • Company acknowledgment on printed meeting materials including but not limited to banners and the program book
  • Digital and printed advertising opportunities 
  • Social media shout-outs
  • Logo on the conference bag 

 
*Subject to the support level.

Endorsers
Endorsing Organizations
Media
Invitation to LAAI 2025 – Hear from Dr. Charles Flexner!

Join us for the 1st International Workshop on Long Acting Anti-Infectives (LAAI) 2025!

Watch as Dr. Charles Flexner shares why this workshop is a must-attend program for anyone working in long-acting and extended-release therapeutics.

Don’t miss this opportunity to engage with experts, discuss the latest advancements, and shape the future of long-acting anti-infectives!

Language
Related Programs
Afbeelding
Michelle 2022
Caption
Hi! I’m Michelle
Label / Name
How can I help you?
Go to Contact form webform